紫杉醇
磷酸化
微管蛋白
微管
长春碱
DNA损伤
细胞生物学
激酶
化学
微管聚合
蛋白质磷酸化
蛋白激酶A
磷酸化级联
癌症研究
生物
生物化学
DNA
癌症
化疗
遗传学
作者
Mikhail V. Blagosklonny,Paraskevi Giannakakou,Wafik S. El‐Deiry,David G. I. Kingston,Penelope I. Higgs,L M Neckers,Tito Fojo
出处
期刊:PubMed
日期:1997-01-01
卷期号:57 (1): 130-5
被引量:386
摘要
Recent studies have shown that paclitaxel leads to activation of Raf-1 kinase and have suggested that this activation is essential for bcl-2 phosphorylation and apoptosis. In the present study, we demonstrate that, in addition to paclitaxel, other agents that interact with tubulin and microtubules also induce Raf-1/bcl-2 phosphorylation, whereas DNA-damaging drugs, antimetabolites, and alkylating agents do not. Activation of Raf-1 kinase by paclitaxel is linked to tubulin polymerization; the effect is blunted in paclitaxel-resistant cells, the tubulin of which does not polymerize following the addition of paclitaxel. In contrast, vincristine and vinblastine, drugs to which the paclitaxel-resistant cells retain sensitivity were able to bring about Raf-1 phosphorylation. The requirement for disruption of microtubules in this signaling cascade was strengthened further using paclitaxel analogues by demonstrating a correlation between tubulin polymerization, Raf-1/bcl-2 phosphorylation, and cytotoxicity. Inhibition of RNA or protein synthesis prevents Raf-1 activation and bcl-2 phosphorylation, suggesting that an intermediate protein(s) acts upstream of Raf-1 in this microtubule damage-activating pathway. A model is proposed that envisions a pathway of Raf-1 activation and bcl-2 phosphorylation following disruption of microtubular architecture, serving a role similar to p53 induction following DNA damage.
科研通智能强力驱动
Strongly Powered by AbleSci AI